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Abstract
Background: The island of Anjouan (Comoros) is highly endemic for leprosy with an annual incidence of 5–10/10,
000. In May/June, 2015 single-dose Rifampicin post-exposure prophylaxis (SDR-PEP) was administered to 269 close
contacts of 70 leprosy-patients in four villages as a pilot programmatic intervention. Two years later we revisited the
villages for follow-up investigations. The main aim of our study was to quantify spatial associations between
reported leprosy cases before and after PEP implementation. A secondary aim was to assess the effect of this single
round of SDR-PEP at the individual level.
Methods: We conducted door-to-door leprosy screening in all four villages in August/September, 2017. We
screened all consenting individuals for leprosy and recorded geographic coordinates of their household. We also
recorded whether they had received SDR-PEP and whether they had been diagnosed with leprosy, before or after
the 2015 intervention. We fitted a Poisson model with leprosy as outcome and distance to the nearest pre-
intervention case and SDR-PEP as predictors.
Results: During the survey we found 114 new cases among 5760 contacts screened (2.0% prevalence), in addition
to the 39 cases detected in the two preceding years. We found statistically significant associations of incident
leprosy with physical distance to index cases ranging from 2.4 (95% confidence interval (95% CI) 1.5–3.6) for
household contacts to 1.8 (95% CI 1.3–2.5) for those living at 1–25 m, compared to individuals living at ≥75 m.
The effect of SDR-PEP appeared protective but did not reach statistical significance due to the low numbers, with
an incidence rate ratio (IRR) of 0.6 (95% CI 0.3–1.2) overall, and 0.5 (95% CI 0.2–1.3) when considering only
household contacts.
Conclusions: This pilot demonstrated an increased risk of leprosy in contacts beyond the household, therefore a
wider circle should be considered for chemoprophylaxis. Baseline surveys and extended contact definitions are
essential for improving SDR-PEP effectiveness.
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Background
Leprosy is an infectious disease caused by Mycobacterium
leprae [1]. M. leprae is transmitted through the air [2] and
after an incubation period of several months to 20 years,
provokes skin lesions and nerve damage. Prolonged delay
in diagnosis and treatment may cause permanent disability
[3], which often leads to social stigma [4].
In 1991, the 44th World Health Assembly (WHA) set
the year 2000 as a target to eliminate leprosy as public
health problem, defined as a global prevalence of less
than one leprosy case per 10,000 population [5]. Early
diagnosis and multidrug therapy (MDT) contributed to
attaining this goal, together with changes in case defin-
ition, achieving a prevalence reduction from more than
five million cases in the 1980s to less than 600,000 by
the year 2000 [6]. Nevertheless, the number of new lep-
rosy cases reported annually has remained above 210,
000 since 2013 [7]. Combined with the persistence of
leprosy in children, this implies that there is no decline
of the transmission of M. leprae, a key step needed to
achieve leprosy elimination.
The Global Leprosy Strategy 2016–2020 encourages im-
plementation research on prevention of leprosy, including
chemoprophylaxis [8, 9]. Single dose Rifampicin Post-
Exposure Prophylaxis (SDR-PEP) given to the contacts of
newly diagnosed leprosy cases has been documented as an
effective strategy, reducing leprosy incidence at village/
neighbourhood level by approximately 50–60% [10, 11].
The success of implementing SDR-PEP under program-
matic conditions relies on the integration of passive detec-
tion, active case finding and a strong monitoring and
evaluation system [12]. Learning from the experience with
SDR-PEP implementation of leprosy control programs is
key to help identify its optimal implementation modalities.
The Comoros is an archipelago in the northern
Mozambique Channel in the Indian Ocean. The closest
neighbours are Tanzania (Northwest), Mozambique
(West), Madagascar (South) and Seychelles (Northeast).
Figure 1 shows an overview map of the Comoros. The
country has approximately 810,000 inhabitants [13],
distributed over three islands with distinct geological
features. Of the total population, 51% live on the main
island Grand Comore, 42% on Anjouan, where moun-
tains limit the inhabitable land, and 7% on Mohéli.
Leprosy has all but disappeared from Grand Comore
since 1980, but persists on the two other islands [14].
Despite its modest population size, the Comoros is
considered one of the 22 high leprosy burden countries
[9]. In 2016, the national detection rate was 3.8/10,000
inhabitants. Out of 310 new leprosy cases detected, 83
(27%) were children (below 15 years of age) [7].
On the island of Anjouan, leprosy has been highly
endemic for decades, with a reported incidence above
7/10,000 inhabitants, with more than 30% of new
leprosy cases being children [15]. The leprosy control
program on the Comoros was launched in 1978 and
has since benefitted from the support of two inter-
national non-governmental organizations, Damien
Foundation and AIFO (Associazione Italiana Amici di
Raoul Follereau). Since 1986, tuberculosis (TB) and
leprosy control have been integrated within the Na-
tional Tuberculosis and Leprosy Programme (NTLP).
On Anjouan 27 health facilities offer TB and leprosy
care. The NTLP combines passive and active case
finding to achieve early detection and cure. For active
case finding, leprosy campaigns, where presumptive
leprosy cases are examined in a designated location
(also called ‘camp approach’), and contact tracing are
in place [16]. These control strategies appear to have
been effective in achieving early case detection,
reflected in a proportion of new patients with visible
disabilities of less than 2.5% [15]. The completion rate
of leprosy treatment is also high; rates of above 85%
for both multibacillary (MB) and paucibacillary (PB)
leprosy have been reported for the period 2008 to
2014 [17]. Despite this apparently strong leprosy con-
trol program, the incidence of leprosy remains high.
In 2015, the NTLP decided to pilot implementation of
SDR-PEP for household contacts in four highly endemic
villages of Anjouan. One single round of SDR-PEP was
provided to asymptomatic close contacts of recently
diagnosed leprosy cases, with a focus on household
contacts. The main objective of this intervention was to
assess the feasibility of SDR-PEP under programmatic
conditions and to document the lessons learnt before
embarking on a larger prophylaxis strategy. The main
aim of our study was to quantify spatial associations
between reported leprosy cases before and after the 2015
intervention. The limited sample size precluded an ac-
curate assessment of the effectiveness of SDR-PEP but
we did take it into account as a potential confounder.
Methods
Setting
The study took place on Anjouan, the second largest
island of the Comoros, with approximately 340,000
inhabitants. Anjouan has eight administrative districts,
totalling 93 villages. Case finding for leprosy on Anjouan
is based on a combination of active and passive
approaches.
Four villages with an estimated population of 8400
had been selected for implementing SDR-PEP in May/
June, 2015. A total of 269 consenting close contacts
from 70 households had received SDR-PEP, with rifam-
picin at routine dosing, around 10 mg/kg.
These persons were close contacts, mostly living in the
same household as leprosy patients diagnosed over the
preceding 3½-year period (since January 1st, 2012). In
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this period altogether 176 patients had been diagnosed
in the four villages.
Study design
The study was designed as a retrospective cohort study.
During door-to-door surveys in August/September,
2017, all consenting individuals were examined clinically
for leprosy. For each person examined we recorded
whether or not the person had suffered from leprosy in
the past, whether or not the person had received SDR-
PEP in 2015, and whether or not the person was cur-
rently suffering from leprosy. For past leprosy patients
we recorded the date of diagnosis. The diagnosis of lep-
rosy was made on clinical criteria, following WHO
guidelines [18], including examination for loss of sensa-
tion and nerve enlargement. In addition, skin biopsies
were taken from newly diagnosed all patients identified
during the survey. We also recorded geographic coordi-
nates of all households visited.
Data collection and mapping
All data, including geographical coordinates of house-
holds visited, were recorded using a custom designed
Android application in ‘Open Data Kit’ (ODK). Data
were triangulated with the register of new leprosy pa-
tients and their records on contacts that had received
SDR-PEP. Geographic coordinates of all households
visited were plotted on a map using the Quantum
Geographic Information System (QGIS) software pack-
age, with indication of whether or not there had been
leprosy cases in the 3½-year period pre-intervention
(index cases), or in the 2-year period after the interven-
tion (incident cases).
We then created for all households screened a variable
indicating the distance to the nearest index-case house-
hold ranging from 0m (same household), to 1–25, 26–
50, 51–75, or more than 75 m. Thus, households were
split into five categories of distance to an index-case.
Statistical analyses
We fitted a Poisson model with the count of leprosy
cases detected since July 2015 as dependent variable,
and the log of the population examined as offset. As
independent variables we assessed the five categories of
physical distance to the nearest index case and having
been provided SDR-PEP. Those living at more than 75 m
Fig. 1 Overview map of the Union of Comoros. Map of Comoros and neighboring countries
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were used as reference category. Village of residence was
included by default to control for potential confounding
by contextual factors.
We calculated incidence rate ratios (IRR) and their
95% confidence intervals (95% CI). To assess a potential
interaction between SDR-PEP and physical distance to
an index case, we recoded the distance variable to a
binary variable set to ‘1’ for household contacts and ‘0’
for all others. Bearing in mind that SDR-PEP was pri-
marily provided to household contacts, we did a separate
analysis restricted to household contacts only. A p-value
< 0.05 was considered statistically significant.
Ethics
This study is part of a larger study for which ethical ap-
proval was obtained from the institutional review board
of the Institute of Tropical Medicine and the ethics
committee of the Antwerp university hospital (both in
Belgium), as well as from the ethics committee on
Anjouan (Comoros). All subjects provided verbal con-
sent for screening which was carried out by the national
leprosy control program as part of their active case find-
ing strategy. Leprosy patients identified were enrolled in
the main study (reported separately) after providing
written informed consent. In case of illiterate individ-
uals, a thumb print and a signature of an independent
witness were sought. For minors below the age of 18
years, a parent or guardian provided informed consent.
Results
During the surveys in 2017 we registered a population of
5908, out of which 5760, were screened for leprosy.
Among those were 133 out of 176 former leprosy pa-
tients diagnosed in the 3½-year period before the inter-
vention (January 2012 to May 2015) and 259 out of 269
close contacts who had been provided SDR-PEP in June,
2015. Out of those 259 close contacts, 240 (92.7%) were
household contacts. At the time of the surveys we
detected 114 new cases, equivalent to a prevalence rate
of 198/10,000.
Thirty-nine more cases had been detected previously
in the period since SDR-PEP was provided, resulting in a
cumulative incidence of 153 new cases since June, 2015.
There were statistically significant associations with
physical distance to the nearest index case, the IRR for
household contacts being 2.4 times higher (95% CI 1.5–
3.6) than for those living at more than 75m. For non-
household contacts living within 25 m of an index case
there was still a statistically significant increase in risk
(IRR 1.8, 95% CI 1.3–2.5), beyond 25 m associations be-
came statistically non-significant (see Table 1). The inter-
action term between household contact and SDR-PEP
was statistically not significant (p = 0.23).
Out of the 259 close contacts screened in 2017 who
had received SDR-PEP in 2015, seven (2.7%) had devel-
oped leprosy versus 146 out of 5501 (2.7%) among those
who had not received PEP. Controlling for distance to
the nearest index case and village of residence, the IRR
for SDR-PEP was 0.6 (95% CI 0.3–1.2).
When looking at household contacts only, the effect of
PEP was stronger but still not statistically significant.
Among 240 current household contacts that had received
PEP, six cases had occurred (2.5%) versus 21 among 432
(4.9%) that had not received PEP. Controlling for village
of residence, the incidence rate ratio was 0.5 but similarly
not statistically significant (95% CI 0.2–1.3).
Figure 2 shows the distribution of leprosy patients in
one of the four villages. Despite a very high prevalence
there was still apparent clustering, with incident cases
clustered around index cases but also around other inci-
dent cases.
Discussion
Through door-to-door surveys in four villages on the is-
land of Anjouan of the Comoros that had been targeted
for many years with active case finding activities using a
camp approach (i.e. inviting people with skin conditions
for free diagnostic screening in a central location in the
villages), we found 114 new cases among 5760 contacts
screened (2.0% prevalence). Thirty-nine more cases had
been detected in the two preceding years. The chances
of having leprosy were statistically significantly higher
for those residing close to index cases (< 25m). Two
years earlier, in 2015, 269 close contacts from 70 house-
holds of leprosy patients in these villages had been
provided with a single round of SDR-PEP.
We did assess the potential impact of the intervention
and found that taking into account all contacts the
overall effect of SDR-PEP appeared protective. But as we
knew from the start, due to the low numbers (insuffi-
cient power) this effect was statistically not significant,
with an incidence rate ratio (IRR) of 0.6 (representing a
protective effect of 40%). When considering only
household contacts the protective effect was somewhat
stronger but still statistically not significant, with an in-
cidence rate ratio of 0.5 (representing a protective effect
of 50%). This is comparable with the results of the
COLEP trial, which showed a 57% reduction in leprosy
incidence over a two-year period after SDR-PEP was
provided to contacts, in comparison to placebo [11].
Furthermore, 240 out of 259 contacts provided with PEP
included in our survey (93%) were household contacts
and therefore mainly blood-related. A higher effective-
ness of SDR-PEP can be expected among non-blood
related close contacts [19].
The main focus of our study was to assess the risk of
being diagnosed with leprosy as a function of physical
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Fig. 2 Distribution of index cases (January 2012–June 2015) and incident cases (July 2015–October 2017) in a village on Anjouan (Comoros).
Legend: the map plots the household screened, incident leprosy cases households and incident leprosy cases in a village of Anjouan
Table 1 Frequency and risk of being diagnosed with leprosy in relation to having received SDR-PEP and physical distance (in meters) to
the nearest index case in four villages of Anjouan (Comoros)
Factor Population (n = 5760) (%) No. of leprosy cases (n = 153) (%) IRR (95% CI)
SDR-PEP provided
- Yes 259 (4.5) 7 (2.7) 0.6 (0.3–1.2)
- No 5501 (95.5) 146 (2.7) Ref.
Distance to index case
- Same household 672 (11.7) 27 (4.0) 2.4 (1.5–3.6)
- 1-25 m 1373 (23.8) 49 (3.6) 1.8 (1.3–2.5)
- 26- 50 m 1604 (27.9) 36 (2.2) 1.2 (0.8–1.7)
- 51- 75 m 654 (11.3) 16 (2.4) 1.3 (0.8–2.1)
- > 75 m 1457 (25.3) 25 (1.7) Ref.
SDR-PEP = Single Dose Rifampicin – Post Exposure Prophylaxis, Ref. = reference category
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distance to an index case. Here we found a statistically
significant IRR of 2.4 for household contacts compared
to those living at more than 75m distance. This result is
close to the IRR of 2.1 (CI95% 1.6–2.7) for household
contacts compared to non-contacts found in Malawi by
Fine et al. [20], but lower than the IRR of 9.4 for house-
hold contacts compared to their neighbours found in
Indonesia by Van Beers et al. [21]. The different grading
of IRR could be explained by the type of population and
their leprosy endemicity, however the physical distance
to an index case related to the closeness and intensity of
the contact is clearly the most important risk factor in
our population, as also described elsewhere [22]. We
found statically significant clustering up to 25 m from
any index case.
This is similar to findings from Brazil by Moura et al.
who reported equally high yields of active case finding
among household contacts as among neighbours of
index cases [23]. In our population the mix of different
approaches of case finding could have weakened the
spatial associations between index cases and incident
cases detected because an important number of existing
cases must have been missed at baseline.
In a trial reported by Bakker et al. [24] on highly
endemic islands in Indonesia two doses of Rifampicin
PEP were given three months apart, after which a three-
fold reduction in incidence of leprosy was observed on
islands allocated to blanket treatment (i.e. treating the
entire eligible population), whereas no effect was ob-
served on islands where PEP was provided to household
contacts and neighbours only. The islands in Indonesia
had a high leprosy incidence (0.9% over three years in
the non-intervention group), which is comparable to the
incidence in our study villages on the Comoros (0.6%
the last five years). With such high incidence levels, PEP
given to close contacts alone may not have sufficient im-
pact at the community level because there are many
sources of transmission other than the reported cases.
Such sources may include asymptomatically as well as
symptomatically infected individuals [25, 26]. In such
high prevalence situations, virtually all members of a
community could be considered as a contact and the
whole community would be eligible to a PEP interven-
tion [27–29].
Whereas the Indonesian islands had only a few thou-
sand inhabitants [24], Anjouan has more than 340,000.
Subjecting them all to SDR-PEP seems not very feasible.
If, on the other hand, it could be demonstrated that
transmission clusters mostly within certain (parts of )
high-endemic villages, targeting entire villages or parts
of them would be feasible.
Two important lessons can be learned from this pilot
study. Leprosy geographical clusters in space at the sub-
village level, and targeting not only household members
but also neighbours of index cases with active case
finding and post exposure prophylaxis seems indicated.
Secondly, in an environment with (very) high leprosy in-
cidence, active case finding needs to be intensified prior
to providing SDR-PEP to ensure that there is no hidden
leprosy prevalence, otherwise many contacts of leprosy
patients will not receive SDR-PEP.
Conclusion
This pilot study demonstrated an increased risk of
leprosy in contacts beyond the household, therefore a
wider circle should be considered for chemoprophylaxis.
Baseline surveys and extended contact definitions are
essential for improving SDR-PEP effectiveness.
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